Welcome to DukeHealth.org.
Skip over navigation
  • Home
  • Services
  • Locations
  • Physicians
  • Patient and Visitor Info
  • Clinical Trials
  • Event Calendar
  • Health Library
  • About Duke Medicine

Quick Links

  • Appointments
  • HealthView Patient Login
  • Quality and Safety
Home > Physicians > D'Amico, Thomas A.
Jumbo Large Regular Text:
Print E-mail
Physicians

Thomas A. D'Amico, MD

Related Content

Video

This Is Duke Medicine: Thomas D'Amico, MD

Services

  • Esophageal Cancer Surgery
  • Esophageal Cancer Treatments
  • Esophagus Disorders
  • Lung Cancer Surgery
  • Lung Volume Reduction Surgery
  • Sarcoma
  • Therapeutic and Reconstructive Surgery for Sarcomas
  • Valvular Heart Disease Surgery

Health Library

  • Best Doctors 2011-2012 Award Winners
  • Surgery Patient Story: Al Marsiglia
  • Catch Your Breath
  • Rallying the Lung Cancer Team
  • Lung Cancer: Is “The Blame Game” Hurting our Progress?

Share

Thomas A. D'Amico, MD

Chief, Section of General Thoracic Surgery

Department / Division
Surgery / Cardiovascular & Thoracic

Address
DUMC 3496
Durham, NC 27710

Appointment Telephone
919-684-4891

Office Telephone
919-684-4891

Fax Telephone
919-684-8508

Training
  • MD, Columbia University College of Physicians and Surgeons (New York), 1987

Residency
  • Thoracic Surgery, Duke University Medical Center, 1987-1996

Fellowship
  • Thoracic Oncology, Memorial Sloan-Kettering Cancer Center, 1996

Clinical Interests
Lung and esophageal cancer; general thoracic and thorocoscopic surgery; minimally invasive thoracic surgery; thoracic oncology; lung volume reduction; photodynamic therapy (PDT); laser bronchoscopy; bronchial and esophageal stents; molecular biology of lung and esophageal cancer

Research Interests
Lung Cancer

1.Role of molecular markers in the prognosis and therapy of lung cancer
2.Genomic analysis lung cancer mutations


Esophageal Cancer

1.Role of molecular markers in the prognosis and therapy of esophageal cancer
2.Genomic analysis esophageal cancer mutations

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

  • Covidien
  • Maquet
  • Scanlan

Representative Publications
Joshi MB, D'Amico TA, Harpole DH Jr. Molecular biologic substaging of stage I NSCLC through immunohistochemistry performed on formalin-fixed, paraffin-embedded tissue. Methods Mol Med. 2003;75:369-88. (2003) Abstract

D'Amico TA, Wong TZ, Harpole DH, Brown SD, Coleman RE. Impact of computed tomography-positron emission tomography fusion in staging patients with thoracic malignancies. Ann Thorac Surg. 2002 Jul;74(1):160-3; discussion 163. (2002) Abstract

D'Amico TA. Molecular biologic substaging of non-small cell lung cancer. J Thorac Cardiovasc Surg. 2002 Mar;123(3):409-10. (2002) Abstract

Daniels LJ, Balderson SS, Onaitis MW, D'Amico TA. Thoracoscopic lobectomy: a safe and effective strategy for patients with stage I lung cancer. Ann Thorac Surg. 2002 Sep;74(3):860-4. (2002) Abstract

Lau CL, Moore MB, Brooks KR, D'Amico TA, Harpole DH Jr. Molecular staging of lung and esophageal cancer. Surg Clin North Am. 2002 Jun;82(3):497-523. (2002) Abstract

Aloia TA, Harpole DH Jr, Reed CE, Allegra C, Moore MB, Herndon JE 2nd, D'Amico TA. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg. 2001 Sep;72(3):859-66. (2001) Abstract

D'Amico TA, Aloia TA, Moore MB, Conlon DH, Herndon JE 2nd, Kinch MS, Harpole DH Jr. Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg. 2001 Oct;72(4):1144-8. (2001) Abstract

Harpole DH Jr, Moore MB, Herndon JE 2nd, Aloia T, D'Amico TA, Sporn T, Parr A, Linoila I, Allegra C. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2001 Mar;7(3):562-9. (2001) Abstract

Markert ML, Alvarez-McLeod AP, Sempowski GD, Hale LP, Horvatinovich JM, Weinhold KJ, Bartlett JA, D'Amico TA, Haynes BF. Thymopoiesis in HIV-infected adults after highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2001 Nov 20;17(17):1635-43. (2001) Abstract

D'Amico TA, Aloia TA, Moore MB, Herndon JE 2nd, Brooks KR, Lau CL, Harpole DH Jr. Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg. 2000 Mar;69(3):882-6. (2000) Abstract

D'Amico TA, Harpole DH Jr. Molecular biology of esophageal cancer. Chest Surg Clin N Am. 2000 Aug;10(3):451-69. (2000) Abstract

Lau CL, Palmer SM, Posther KE, Howell DN, Reinsmoen NL, Massey HT, Tapson VF, Jaggers JJ, D'Amico TA, Davis RD Jr. Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients. Ann Thorac Surg. 2000 May;69(5):1520-4. (2000) Abstract

Morse MA, Bossen E, D'Amico TA, Williamson W, Johnson R. Myxoid liposarcoma of the supraclavicular fossa. Chest. 2000 May;117(5):1518-20. (2000) Abstract

Shah AS, Forbess JM, Skaryak LA, Lilly RE, Vaslef SN, D'Amico TA. Emergent thoracotomy for airway control after intrathoracic tracheal injury. J Trauma. 2000 Jun;48(6):1163-4. (2000) Abstract

D'Amico TA, Massey M, Herndon JE 2nd, Moore MB, Harpole DH Jr. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg. 1999 Apr;117(4):736-43. (1999) Abstract

Contact Us | Careers | Privacy Policy | Make a Gift | Site Map | RSS Feeds | En Español | Mobile Site | Help
Duke Medicine | Duke School of Medicine | Duke Children's | Duke University
Toll-Free: 888-ASK-DUKE (888-275-3853)
Copyright © 2004-2012 Duke University Health System

About This Page

Updated: June 27, 2011
Published: Dec. 12, 2006
URL: http://www.dukehealth.org/physicians/thomas_a_damico